

LITERATUR

Adje C, Cheingsong R, Roels TH, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. *J Acquir Immune Defic Syndr* 2001;26:501-6.

Akileswaran C, Lurie MN, Flanigan TP, Mayer KH. Lessons learned from use of highly active antiretroviral therapy in Africa. *Clin Infect Dis* 2005;41:376-85.

Altfeld M, Walker BD. Die akute HIV-Infektion. In: Hoffman C, Rockstroh JK, Kamps BS, eds. *HIV.Net 2005*. Wuppertal-Beyenburg, Deutschland: Steinhäuser Verlag, 2005:81-87.

Arndt C, Lewis J. The macro implications of HIV/AIDS in South Africa: a preliminary assessment. *S Afr J Econ* 2000;68:1-32.

Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. *Clin Infect Dis* 2001;33:1417-23.

Auswärtiges Amt. Länderinformationen. Berlin: Auswärtiges Amt, 2006. (Accessed at January 17, 2006, at <http://www.auswaertiges-amt.de/www/de/laenderinfos/index.html>.)

Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. *AIDS* 2000;14:357-66.

Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. *J Antimicrob Chemother* 2004;53:696-9.

Bangsberg DR, Ware N, Simoni JM. Adherence without access in sub-Saharan Africa? *AIDS* 2006;20:140-1.

Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. *AIDS* 2001;15:1369-77.

Bartlett JG, Gallant JE. Drug Information. In: Bartlett JG, Gallant JE, eds. *Medical Management of HIV Infection*. Baltimore, USA: Johns Hopkins Medicine Health Publishing Business Group, 2004:123-302.

Baylor MS, Johann-Liang R. Hepatotoxicity associated with Nevirapin use. *JAIDS* 2004;35:538-9.

Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. USA, 2004. (Accessed January 15, 2006, at <http://aidsinfo.nih.gov/Guidelines/Default.aspx?MenuItem=Guidelines&Search=On>.)

Byakika-Tusiime J, Oyugi JH, Tumwirikize WA, Katabira ET, Mugenyi PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. *Int J STD AIDS* 2005;16:38-41.

CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR* 1993;41:RR17.

CDC. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures worldwide, 1997–2000. *MMWR* 2001;49:1153–6.

Coetzee D, Hildebrand K, Boule A, et al. Outcomes after two years of providing antiretroviral treatment in Kayelitsha, South Africa. *AIDS* 2004;18:887-95.

Colebunders R, Ronald A, Katabira E, Sande M. Rolling out antiretrovirals in Africa: there are still challenges ahead. *Clin Infect Dis* 2005;41:386-9.

Colebunders R, Moses KR, Laurence J, et al. A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. *Lancet Inf Dis* 2006;6:53-9.

Crowe S, Turnbull S, Oelrichs R, Dunne A. Monitoring of human immunodeficiency virus infection in resource-constrained settings. *Clin Infect Dis* 2003;37(suppl 1):S25-S35.

Deeks SG. Determinants of virological response in antiretroviral therapy: implications for long-term strategies. *Clin Infect Dis* 2000;30(suppl 3):S177-84.

Del Rio C, Priddy F. Outcomes for patients receiving antiretroviral therapy in the developing world appear to be not much different from those in the developed world. *Clin Infect Dis* 2005;41:225-6.

Department of Health and Human Services. Panel on clinical practices for treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Supplement 1: Considerations of antiretroviral therapy in women. USA: 2004. (Accessed February 24, 2006, at <http://www.aidsinfo.nih.gov/>.)

Department of Health and Human Services. Panel on clinical practices for treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. USA: 2005. (Accessed January 15, 2006, at <http://www.aidsinfo.nih.gov/>.)

Djomand G, Roels T, Ellerbrock T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. *AIDS* 2003;17(suppl 3):S5-S15.

Dobkin JF. South African antiretroviral rollout. *Infect Med* 2004;21:152,162

Drake JW. Rates of spontaneous mutation among RNA viruses. *Proc Natl Acad Sci USA* 1993;90:4171-5.

Egger M, May M, Chêne G, et al., Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet* 2002;360:119-29.

Ekouevi DK, Leroy V, Viho A, et al. Acceptability and uptake of a package to prevent mother-to-child transmission using rapid HIV testing in Abidjan, Cote d' Ivoire. *AIDS* 2004;18:697-700.

Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent Antiretroviral treatment: Swiss HIV Cohort Study. *Lancet* 2001;358:1322-7.

Garcia F, De Lazzari E, Plana M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. *J Acquir Immune Defic Syndr* 2004;36:702-713.

Gesellschaft für technische Zusammenarbeit (GTZ). Soziale Krankenversicherung in Kenia. GTZ Sektorvorhaben. Bonn / Eschborn: GTZ, 2003. (Accessed January 17, 2006, at <http://www.gtz.de/de/themen/soziale-enteicklung/soziale-sicherheit/13681.htm>.)

Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. *J Acquir Immune Defic Syndr* 2000;23:386-95.

Gill CJ, Hamer DH, Simon JL, Thea DM, Sabin LL. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. *AIDS* 2005;19:1243-9.

Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. *HIV Clin Trials* 2004;5:74-9.

Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. *J Gen Intern Med* 2002;17:756-65.

Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of HAART. *Ann Int Med* 2000;133:401-10.

Gulick RM, Meibohm A, Havlir D, et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudin, and lamivudin. *AIDS* 2003;17:2345-9.

Gulick RM, da Silva B, McMillan F, et al. Lopinavir/Ritonavir (LPV/r)-based therapy in antiretroviral (ARV)-naïve, HIV-infected patients: 6-year follow-up of study 720. Abstract P28, 7th Int Congress Drug Ther HIV Inf, 2004, Glasgow, Ireland.

Harries, AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, Salanipodi FN. Preventing antiretroviral anarchy in sub-Saharan Africa. *Lancet* 2001;358:404-9.

Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. *AIDS* 1999;13:1099-107.

Hira SK, Panchal K, Parmar PA, Bhatia VP. High resistance to antiretroviral drugs: the Indian experience. *Int J STD AIDS* 2004;15:173-7.

Hitti J, Frenkel LM; Stek AM, et al. Maternal toxicity with continuous nevirapin in pregnancy. Results from PACTG 1022. *J Acquir Immune Defic Syndr* 2004;36:772-6.

Hugen PW, Langebeek N, Burger DM, et al. Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. *J Acquir Immune Defic Syndr* 2002;30:324-34.

Imperiale SM, Stern JO, Love JT et al. The VIRAMUNE (nevirapin) safety project: analysis of symptomatic hepatitis events. Abstract 87, 4th International Workshop of Adverse Events and Lipodystrophy in HIV. September 22-25, 2002. San Diego, CA, USA.

International AIDS Society (IAS). Place of antiretroviral drugs in the treatment of HIV-infected people in Africa. *AIDS* 1999;13:IAS1-IAS3

Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. *Clin Infect Dis* 2005;41:217-24.

Jaffar S, Govdner T, Garrib A, et al. Antiretroviral treatment in resource-poor settings: public health research priorities. *Trop Med Int Health* 2005;10:295-9.

Joao EC, Calvet GA, Menezes JA, et al. Nevirapin toxicity in a cohort of HIV-1 infected pregnant women. *Am J Obstet Gynecol* 2006;194:199-202.

Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal response to nevirapin-based antiretroviral therapy. *N Engl J Med* 2004;351:229-40.

Kabugo C, Bahendeka S, Mwebaze R, et al. Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda. *J Acquir Immune Defic Syndr* 2005;38:578-83.

Karcher H, Boehning D, Downing R, Mashate S, Kunz A, Harms G. Comparison of two alternative methods for CD4+ T-cell determination (Coulter Manual CD4 count and CyFlow) against standard dual platform flow cytometry in Uganda. *Cytometry B Clin Cytom* 2006;70:163-9.

Karcher H, Kunz A, Pogensee G, Mbezi P, Mugenyi K, Harms G. Outcome of different nevirapine administration strategies in PMTCT programmes in Tanzania and Uganda. *MedGenMed* 2006;8:12.

Kasper T, Coetzee D, Louis F, Boulle A, Hildebrand K. Demystifying antiretroviral therapy in resource-poor settings. *Essent Drug Monit* 2003;32:20-1.

Katzenstein D, Laga M, Moatti JP. The evaluation of the HIV/AIDS drug access initiatives in Côte d'Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa, *AIDS*;2003;17(suppl 3):S1-S4.

Kimalu PK, Nafula NN, Manda DK, Bedi A, Mwabu G, Kimenyi MS. A review of the health sector in Kenya. Social sector division. Kenya Institute for Public Policy Research and Analysis (KIPPRA). KIPPRA working paper no. 11, 2004. (Accessed January 17, 2006, at <http://www.eldis.org/static/DOC17489.htm>.)

Koher K, van Damme W. Scaling up access to antiretroviral treatment in southern Africa: who will do the job? *Lancet* 2004;346:103-7.

Koenig SP, Léandre F, Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. *AIDS* 2004;18(suppl 3):S21-S25.

Kumar S. India's treatment programme for AIDS is premature. *BMJ* 2004;328:70.

Kumarasamy N, Vallabhaneni S, Cecilia AJ, et al. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in Southern India. *J Acquir Immune Defic Syndr* 2006;41:53-58.

Laine C, Newschaffer CJ, Zhang D, Cosler L, Hauck WW, Turner BJ. Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. *Obstet Gynecol* 2000;95:167-73.

Landmann R, Schiemann R, Thiam S. Once-a-day highly active antiretroviral therapy in treatment-naïve HIV-1 infected adults in Senegal. *AIDS* 2003;17:1017-22.

Lanièce I, Ciss M, Desclaux A, et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. *AIDS* 2003;17(suppl 3):S103-S108.

Laurent C, Diakhate N, Gueye NF, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. *AIDS* 2002;16:1363-70.

Laurent C, Gueye NF, Ndour CT, et al. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1 infected adults. *J Acquir Immune Defic Syndr* 2005a;38:14-17.

Laurent C, Kouanfack C, Koulla-Shiro S, et al., Effectiveness and safety of a generic fixed-dose combination of nrvirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. *Lancet* 2004;364:29-34.

Laurent C, Meilo H, Guiard-Schmid JB, et al. Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. *Clin Infect Dis* 2005b;41:108-11.

Lazzari S, de Felici A, Sobel H, Bertagnolio S. HIV drug resistance surveillance: summary of an april 2003 WHO consultation. *AIDS* 2004;18(suppl 3):S49-S53.

Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. *Lancet* 2004;364:51-62.

Liechty CA, Alexander CS, Harrigan PR, et al. Are untimed antiretroviral drug levels useful predictors of adherence behavior? *AIDS* 2004;18:127-9.

Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. *Ann Intern Med* 2001;134:968-77.

Loewenson R, McCoy D. Access to antiretroviral treatment in Africa. *BMJ* 2004;328:241-2

Luppe T, Kreischer S. Ärzte ohne Grenzen e.V. Patentschutz und die Zukunft des Medikamentenzugangs in armen Ländern. Berlin: Ärzte ohne Grenzen e.V., 2004.

Machtiger EL, Bangsberg DR. Adherence to HIV antiretroviral therapy. HIV insite knowledge base chapter. USA, 2005. (Accessed January 15, 2006, at <http://hivinsite.ucsf.edu/InSite?page=kb-03-02-09>.)

Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effect of antiretroviral therapy on body composition in HIV-1 infected men starting therapy. *AIDS* 2003;17:971-9.

Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from thymidine analogue to abacavir: the MITOX Extension Study. *AIDS* 2004;18:1029-36.

McComsey GA, Ward DJ, Hesselthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudin to abacavir or zidovudine: the results of the TARHEEL study. *Clin Infect Dis* 2004;38:263-70.

McCoy D, Chopra M, Loewenson R, et al. Expanding access to antiretroviral therapy in sub-Saharan Africa: avoiding pitfalls and dangers, capitalizing on the opportunities. *Am J Public Health* 2005;95:18-22.

McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. *Clin Infect Dis* 2001;33:700-5.

McNabb JJ, Nicolau DP, Stoner JA, Ross J. Patterns of adherence to antiretroviral medications: the value of electronic monitoring. *AIDS* 2003;17:1763-7.

Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. *Ann Intern Med* 1995;122:573-9.

Ministry of Health, Kenya. Figures of the health system. Ministry of Health, Kenya, 1999. (Accessed on January 17, 2006, at <http://www.ministryofhealth.go.ke/index.html>.)

Ministry of Health, Kenya. National AIDS and STD Control Programme. Guidelines to antiretroviral drug therapy in Kenya. Ministry of Health, Kenya, 2002.

Moatti JP, Spire B, Kzatchkine M. Drug resistance and adherence to HIV/AIDS antiretroviral treatment: against a double standard between the north and the south. *AIDS* 2004;18(suppl 3):S55-S61.

Mocroft A, Brettle R, Kirk O et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. *AIDS* 2002;16:1663-71.

Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? *J Acquir Immune Defic Syndr* 2000;24:475-82.

Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study. *Lancet* 2000;356:291-6.

Moore AL, Kirk O, Johnson AM, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. *J Acquir Immune Defic Syndr* 2003;32:452-61.

Murri R, Ammassari A, Gallicano K, et al. Patient-reported nonadherence to HAART is related to protease inhibitor levels. *J Acquir Immune Defic Syndr* 2000;24:123-8.

Mwamburi DM, Wilson IB, Jacobson DL, et al. Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy. *Clin Infect Dis* 2005;40:167-73.

Nachega JB, Stein DM, Lehman DA, et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. *AIDS Res Hum Retroviruses* 2004;20:1053-6.

National Institute of Allergy and Infectious Diseases. Division of AIDS (DIADS). Table for grading severity of adult adverse experiences for the HIV Prevention Trials Network. National Institutes of Health, Bethesda, MA. USA: 2006 (Accessed March 6, 2006, at <http://www.niaid.nih.gov/daids/>.)

Nicastrì E, Angeletti C, Palmisano L, et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. *AIDS* 2005;19:577-83.

Niehus T. Antiretrovirale Therapie bei Kindern. In: Hoffmann C, Rocksroh JK, Kamps BS, eds. HIV.NET 2005. Wuppertal-Beyenburg, Deutschland: Steinhäuser Verlag, 2005:347-363.

O'Brien ME, Clark RA, Besch CL, et al. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. *J Acquir Immune Defic Syndr* 2003;34:407-14.

Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. *AIDS* 2003;17:1369-75.

Oyugi JH, Byakika-Tusime J, Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. *J Acquir Immune Defic Syndr* 2004a;36:1100-1102.

Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment outcomes and adherence to generic Triomune and Maxivir therapy in Kampala, Uganda. Abstract WeORB 1323, 15th International AIDS Conference, 2004b, Bangkok, Thailand.

Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced HIV infection. *N Engl J Med* 1998;338:853-60.

Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. *Ann Intern Med* 2000;133:21-30.

Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. *Science* 1996;271:1582-6.

Perinatal HIV Guidelines Working Group. Public Health Service Task Force. Recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 Transmission in the United States. USA: 2005. (Accessed January 14, 2006, at <http://www.aidsinfo.nih.gov/>.)

Phanupak P. Antiretroviral treatment in resource-poor settings: what can we learn from the existing programmes in Thailand? *AIDS* 2004;18(suppl 3):S33-S38.

Phillips AN, Miller V, Sabin C, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naïve individuals. *AIDS* 2001;15:2379-84.

Piot P, Bartos M, Ghys PD, Walker N, Schwartländer B. The global impact of HIV AIDS. *Nature* 2001;410:968-73.

Reynolds SJ, Bartlett JG, Quinn TC, Beyrer C, Bollinger RC. Antiretroviral therapy where resources are limited. *N Engl J Med* 2003;348:1806-9.

Richard N, Juntilla M, Abraha A, et al. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. *AIDS Res Hun Retroviruses* 2004;20:355-64.

Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. *J Infec Dis* 2005;191:825-9.

Schwartländer B, Garnett G, Walker N, Anderson R. AIDS in a new millennium. *Science* 2000;289:64-7.

Sedgh G, Larsen U, Spiegelman D, Msamanga G, Fawzi WW. HIV-1 disease progression and fertility in Dar es Salaam, Tanzania. *J Acquir Immune Defic Syndr* 2005;39:439-45.

Sethi AK, Celentano DD, Gange SJ, et al. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. *Clin Infect Dis* 2003;37:1112-8.

Stevens W, Kaye S, Corrah T. Antiretroviral therapy in Africa. *BMJ* 2004;328:280-2.

Seyler C, Anglaret X, Dakoury-Dogbo N, et al. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire. *Antivir Ther* 2003;8:385-93.

Spacek LA, Shihab HM, Kanya MR, et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. *Clin Infect Dis* 2006;42:252-9.

Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. *N Engl J Med* 1999;341:1865-73.

Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. *AIDS* 2001;15:2251-7.

Stern JO, Robinson PA, Love J, et al. A comprehensive safety analysis of nevirapin in different populations of HIV-infected patients. *J Acquir Immune Defic Syndr* 2003;34:S21-S33.

Stevens W, Kaye S, Corrah T. Antiretroviral therapy in Africa. *BMJ* 2004;328:280-2.

Stringer JS, Sinkala M, Stout JP, et al. Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings. *J Acquir Immune Defic Syndr* 2003;32:506-13.

Teixeira PR, Vitória MA, Barcarolo J. Antiretroviral treatment in resource-poor settings: the Brazilian experience. *AIDS* 2004;18(suppl 3):S5-S7.

The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. *Lancet* 2006;367:817-24.

The European Collaborative Study and the Swiss Mother + Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. *AIDS* 2000;14:2913-20.

The Global Fund to Fight AIDS, Tuberculosis and Malaria. Geneva: GFATM, 2006. (Accessed 24 January, 2006, at: <http://www.theglobalfund.org/en/>.)

The World Health Report 2005. World Health Organisation. Geneva: WHO, 2005. (Accessed January 17, 2006, at <http://www.who.int/whr/2005/en/>.)

Tuomala RE, Shapiro D, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002;346:1863-70.

UNAIDS. Access to drugs. UNAIDS technical update. Geneva: UNAIDS, 1998. (Accessed January 14, 2006 at: <http://www.unaids.org/>.)

UNAIDS. The UNAIDS HIV Drug access initiative. Providing wider access to HIV-related drugs in developing countries. Pilot phase. Report of the meeting on the evaluation of the initiative. Geneva: UNAIDS, 2000.

UNAIDS. Summary of the declaration of commitment on HIV / AIDS. United Nations General Assembly Special Session on HIV / AIDS, 25-27 June 2001, New York. Geneva: UNAIDS, 2002. (Accessed January 24, 2006, at: http://www.unaids.org/en/events/un+special+session+on+hiv_aids.asp.)

UNAIDS / WHO. AIDS Epidemic update. Geneva: UNAIDS, 2005. (Accessed January 20, 2006, at <http://www.unaids.org/>.)

United Nations Children's Fund. The Progress of Nations 2000. New York: UNICEF, 2000. (Accessed January 27, 2006, at <http://www.unicef.org/pon00/>.)

United Nations High Commissioner for Human Rights. The right of everyone to the enjoyment of the highest attainable standard of physical and mental health. Commission on Human Rights Resolution 2002/31. Geneva: UNHCR, 2001. (Accessed January 23, 2006, at <http://www.unhcr.ch/>.)

Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-63.

Valdiserri RO, Holtgrave DR, West GR. Promoting early HIV diagnosis and entry into care. *AIDS* 1999;13:2317-30.

Van der Valk M, Casula M, van Kuyk C, et al. Relation between use of nucleoside reverse transcriptase inhibitors, mitochondrial DNA depletion, and severity of lipodystrophy: results from a randomized trial comparing stavudin and zidovudin-based antiretroviral therapy. Abstract 739, 10th CROI, 2003, Boston, USA.

Van Oosterhout JJ, Bodasing N, Kumwenda JJ, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. *Trop Med Int Health* 2005;10:464-70.

Vergne L, Malonga-Mouellet G, Mistoul I, et al. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. *J Acquir Immune Defic Syndr* 2002;29:165-8.

Wagner GJ. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. *AIDS Patient Care STDS* 2002; 16:599-608.

Walsh JC MS, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. *AIDS* 2002;16:269-77.

Weidle PJ, Downing R, Sozi C, et al. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV drug access initiative – Uganda. *AIDS* 2003;17(suppl 3):S39-48.

Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. *Lancet* 2002;360:34-40.

Weiser S, Wolfe W, Bangsberg DR, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. *J Acquir Immune Defic Syndr* 2003;34:281-8.

Wheeler DA. Weight loss and disease progression in HIV infection. *AIDS Read* 1999;9:347-53.

WHO. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. Geneva: WHO, 2003. (Accessed January 14, 2006, at [http://www.who.int/hiv/.](http://www.who.int/hiv/))

WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection infants. Guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings. Geneva: WHO, 2004.

WHO. Antiretroviral drugs for the treatment of HIV infection in adults and adolescents in resource-limited settings. Recommendations for a public health approach (2005-2006 revision). Guidelines Development Group. Brief meeting report. Geneva: WHO, 2005a (Accessed January 14, 2006, at [http://www.who.int/3by5/mediacentre/news51/en/.](http://www.who.int/3by5/mediacentre/news51/en/))

WHO. Antiretroviral drugs and the prevention of mother-to-child transmission of HIV infection in resource-limited settings. Recommendations for a public health approach (2005 revision). Geneva: WHO, 2005b. (Accessed January 14, 2006, at [http://www.who.int/3by5/mediacentre/news51/en/.](http://www.who.int/3by5/mediacentre/news51/en/))

WHO. Country information Kenya. Geneva: WHO, 2005c. (Accessed January 17, 2006, at [http://www.who.int/countries/ken/en/.](http://www.who.int/countries/ken/en/))

WHO. WHO Prequalification Project. Department of Medicines Policy and Standards. Access to HIV/AIDS drugs and diagnostics of acceptable quality. Geneva: WHO 2006. (Accessed January 15, 2006, at [http://mednet3.who.int/prequal/.](http://mednet3.who.int/prequal/))

WHO 3by5 Initiative. Summary country profile for HIV / AIDS treatment scale-up. Geneva: WHO, 2005. (Accessed January 18, 2006 at [http://www.who.int/3by5/support/june2005_ken.pdf.](http://www.who.int/3by5/support/june2005_ken.pdf))

WHO/UNAIDS. Provisional WHO / UNAIDS secretariat recommendations for the use of cotrimoxazole prophylaxis in adults and children living with HIV / AIDS in Africa. Geneva: WHO/UNAIDS, 2000.

WHO/UNAIDS. Progress on global access to HIV antiretroviral therapy. An update on “3by5”. Geneva: WHO, 2005. (Accessed January 19, 2006, at [http://www.who.int/3by5/progressreportJune2005/en/.](http://www.who.int/3by5/progressreportJune2005/en/))

Wools-Kaloustian K, Kimaiyo S, Diero L, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-saharan Africa: experience from western Kenya. *AIDS* 2006;20:41-8.

World Trade Organization (WTO). Declaration on the TRIPS Agreement and Public Health, Absatz 6, Declaration on the TRIPS Agreement and Public Health, World Trade Organization Ministerial Conference, Doha, 9.-14. November 2001, angenommen am 14. November 2001, WT/MIN(01)/DEC/2, 20. November 2001, Para. 7. Geneva: WTO, 2001. (Accessed January 23, 2006, at: [http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.pdf.](http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.pdf))

World Trade Organization (WTO). Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health. Decision of the General Council of 30 August 2003, WT/L/540. Geneva: WTO, 2003. (Accessed January 23, 2006, at: [http://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm.](http://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm))

Zewdie D, Lange J, Kuritzkes D. Editorial. *AIDS* 2004;18(suppl 3):S1-S3.

Zorrilla CD, Santiago LE, Knubson D, et al. Greater adherence to highly active antiretroviral therapy (HAART) between pregnant versus non-pregnant women living with HIV. *Cell Mol Biol* 2003;49:1187-92.